PD-L1 Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

All PD-L1 reagents are produced in house and quality controlled, including 37 PD-L1 Antibody, 2 PD-L1 ELISA, 66 PD-L1 Gene, 2 PD-L1 IP Kit, 12 PD-L1 Lysate, 17 PD-L1 Protein, 3 PD-L1 qPCR. All PD-L1 reagents are ready to use.

PD-L1 Protein (17)

PD-L1 Antibody (37)

    PD-L1 ELISA Kit & Match Antibody ELISA Pair Set (2)

    PD-L1 cDNA Clone (66)

    NM_014143.2
    NM_021893.2
    NM_001191954.1
    EF444816.1
    XM_541302.3
    XM_008255121.2

    In expression vector

    PD-L1 Lysate (12)

      More Product Popular With Customers

      PD-L1 Background

      Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

      PD-L1 References

      • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
      • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
      • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
      • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
      • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.

      Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.